Literature DB >> 32856228

Predicting Positive Margins in Pancreatic Head Adenocarcinoma After Neoadjuvant Therapy: Investigating Disparities in Quality Care Using the National Cancer Database.

Corey Suraci1, Katelyn Young1, James Dove1, Mohsen Shabahang1, Joseph Blansfield2.   

Abstract

BACKGROUND: In pancreatic cancer, surgical resection with neoadjuvant therapy improves survival, but survival relies significantly on the margin status of the resected tissue. This study aimed to develop a model that predicts margin positivity, and then to identify facility-specific factors that influence the observed-to-expected (O/E) ratio for positive margins among facilities.
METHODS: This retrospective review analyzed patients in the National Cancer Database (2004-2016) with pancreatic head adenocarcinoma [tumor-node-metastasis (TNM) stage 1 or 2] who received neoadjuvant therapy for a pancreaticoduodenectomy. Logistic regression was used to develop a model that predicts margin positivity. This model then was used to identify outlier facilities with regard to the O/E ratio. Hospital volume was defined as the total number of pancreaticoduodenectomies per year.
RESULTS: The study enrolled 4085 patients, and 16.8% of these patients had positive margins. Most of the patients (64%) had a tumor size of 2 to 4 cm, and approximately 51% of the patients did not have positive lymph nodes at resection. A logistic regression model showed that the predictors of positive margins after resection with neoadjuvant therapy were male sex, larger tumor size, and positive lymph nodes. This model was validated to yield a bootstrap-corrected concordance index of 0.632. The study calculated O/E ratios with the model, identifying 12 low- and 17 high O/E-ratio outlier facilities among 401 studied hospitals. The outlier hospitals did not differ in facility type (i.e., academic vs integrated network), but did differ significantly in terms of yearly hospital volume (low outlier of 20.6 vs high outlier of 10.7; p = 0.008).
CONCLUSIONS: An association of lower-volume facilities with higher than expected rates of positive margins was found to indicate a disparity in care. This disparity was identified via an O/E ratio as a quality indicator for facilities. Facilities can gauge the efficiency of their own practices by referencing their O/E ratios, and they also can improve their practices by analyzing the framework of low O/E-ratio facilities.

Entities:  

Mesh:

Year:  2020        PMID: 32856228     DOI: 10.1245/s10434-020-08766-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients.

Authors:  Linda M Youngwirth; Daniel P Nussbaum; Samantha Thomas; Mohamed A Adam; Dan G Blazer; Sanziana A Roman; Julie A Sosa
Journal:  J Surg Oncol       Date:  2017-04-13       Impact factor: 3.454

2.  National assessment of margin status as a quality indicator after pancreatic cancer surgery.

Authors:  Ryan P Merkow; Karl Y Bilimoria; David J Bentrem; Henry A Pitt; David P Winchester; Mitchell C Posner; Clifford Y Ko; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2013-12-13       Impact factor: 5.344

3.  Outcome Prediction After Coronary Surgery and Redo Surgery for Bleeding (From the KROK Registry).

Authors:  Piotr Knapik; Daniel Cieśla; Wojciech Saucha; Małgorzata Knapik; Michał O Zembala; Piotr Przybyłowski; Bogusław Kapelak; Mariusz Kuśmierczyk; Marek Jasiński; Zdzisław Tobota; Bohdan J Maruszewski; Marian Zembala
Journal:  J Cardiothorac Vasc Anesth       Date:  2019-05-02       Impact factor: 2.628

4.  Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base.

Authors:  Lauren E Colbert; William A Hall; Dana Nickleach; Jeffrey Switchenko; David A Kooby; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; John Kauh; Jerome C Landry
Journal:  Cancer       Date:  2014-01-03       Impact factor: 6.860

5.  Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis.

Authors:  Ali A Mokdad; Rebecca M Minter; Hong Zhu; Mathew M Augustine; Matthew R Porembka; Sam C Wang; Adam C Yopp; John C Mansour; Michael A Choti; Patricio M Polanco
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

6.  The role of surgery for pancreatic cancer: a 12-year review of patient outcome.

Authors:  S A Badger; J L Brant; C Jones; J McClements; M B Loughrey; M A Taylor; T Diamond; L D McKie
Journal:  Ulster Med J       Date:  2010-05

7.  Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer.

Authors:  Karl Y Bilimoria; Mark S Talamonti; Stephen F Sener; Malcolm M Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  J Am Coll Surg       Date:  2008-06-30       Impact factor: 6.113

8.  Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.

Authors:  Christophe Cassinotto; Anthony Dohan; George Zogopoulos; Laurence Chiche; Christophe Laurent; Antonio Sa-Cunha; Adeline Cuggia; Caroline Reinhold; Benoît Gallix
Journal:  Eur J Radiol       Date:  2017-07-03       Impact factor: 3.528

9.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

10.  Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins.

Authors:  Anna Torgeson; Ignacio Garrido-Laguna; Randa Tao; George M Cannon; Courtney L Scaife; Shane Lloyd
Journal:  ESMO Open       Date:  2018-01-27
  10 in total
  1 in total

1.  Concepts and Outcomes of Perioperative Therapy in Stage IA-III Pancreatic Cancer-A Cross-Validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT).

Authors:  Louisa Bolm; Sergii Zemskov; Maria Zeller; Taisuke Baba; Jorge Roldan; Jon M Harrison; Natalie Petruch; Hiroki Sato; Ekaterina Petrova; Hryhoriy Lapshyn; Ruediger Braun; Kim C Honselmann; Richard Hummel; Oleksii Dronov; Alexander V Kirichenko; Monika Klinkhammer-Schalke; Kees Kleihues-van Tol; Sylke R Zeissig; Dirk Rades; Tobias Keck; Carlos Fernandez-Del Castillo; Ulrich F Wellner; Rodney E Wegner
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.